Insight Molecular Diagnostics Inc. Balance Sheet
IMDX|6 years of annual SEC 10-K data (FY2020-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 6 fiscal years. All figures from audited SEC 10-K filings.
Insight Molecular Diagnostics Inc. had $26M in total assets with negative shareholders' equity of $12M as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -7.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.6M | $8.6M | $9.4M | $20.0M | $35.6M | $7.1M |
| Accounts Receivable | $1.1M | $1.6M | $484.0K | $2.0M | $1.4M | $203.0K |
| Inventory | $446.0K | $410.0K | - | - | - | - |
| Current Assets | $15.3M | $11.8M | $10.7M | $25.5M | $39.1M | $9.2M |
| PP&E (Net) | $9.3M | $6.0M | $4.7M | $8.7M | $7.3M | $4.4M |
| Goodwill | - | - | - | $9.5M | $9.2M | $9.2M |
| Total Assets | $25.8M | $35.1M | $74.9M | $100.1M | $159.6M | $55.4M |
| Current Liabilities | $12.1M | $7.3M | $7.2M | $12.1M | $14.1M | $9.0M |
| Shareholders' Equity | -$12.3M | $20.5M | $34.3M | $65.2M | $33.5M | $30.8M |